论文部分内容阅读
50例T2DM早期DN患者随机分为治疗组(瑞格列奈联合甘精胰岛素),对照组(单纯使用诺和灵30R),观察两组血糖控制,测定,低血糖发生次数。治疗时间12周。结果:两组FPG,2hPG,HbA1c,24小时尿微量白蛋白(UAE)均较治疗前降低(P<0.05),且治疗组低血糖发生次数少(P<0.01)。结论:甘精胰岛素联合瑞格列奈能有效,平稳控制24小时血糖,低血糖反应少,有利于全天血糖控制。
Fifty patients with early stage DN with early DN were randomly divided into treatment group (repaglinide combined with insulin glargine) and control group (noradren 30R alone). The incidence of hypoglycemia and blood glucose control were observed in two groups. Treatment time of 12 weeks. Results: The levels of FPG, 2hPG, HbA1c and UAE in 24 hours were lower than those before treatment (P <0.05), and the incidence of hypoglycemia in the treatment group was less (P <0.01). Conclusion: Glargine combined with repaglinide can effectively and steadily control 24-hour blood glucose and less hypoglycemic reaction, which is beneficial to the control of blood glucose throughout the day.